ES2167189A1 - Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos - Google Patents

Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos

Info

Publication number
ES2167189A1
ES2167189A1 ES009902769A ES9902769A ES2167189A1 ES 2167189 A1 ES2167189 A1 ES 2167189A1 ES 009902769 A ES009902769 A ES 009902769A ES 9902769 A ES9902769 A ES 9902769A ES 2167189 A1 ES2167189 A1 ES 2167189A1
Authority
ES
Spain
Prior art keywords
intravenous
pharmaceutical formulation
intramuscular
octreotide
octreotide administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009902769A
Other languages
English (en)
Other versions
ES2167189B1 (es
Inventor
Obiols Berta Ponsati
Farres Gemma Jodas
Rodriguez Francisco J Clemente
Cabado Jordi Bacardit
Cabado Jordi Baacardit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GP Pharm SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009902769A priority Critical patent/ES2167189B1/es
Application filed by Lipotec SA filed Critical Lipotec SA
Priority to CA2362772A priority patent/CA2362772C/en
Priority to MXPA01008349A priority patent/MXPA01008349A/es
Priority to AU21736/01A priority patent/AU763779B2/en
Priority to AT00985268T priority patent/ATE233105T1/de
Priority to PT00985268T priority patent/PT1153615E/pt
Priority to DE60001489T priority patent/DE60001489T2/de
Priority to JP2001544912A priority patent/JP4912551B2/ja
Priority to PCT/ES2000/000476 priority patent/WO2001043776A1/es
Priority to DK00985268T priority patent/DK1153615T3/da
Priority to US09/913,439 priority patent/US6521599B2/en
Priority to ES00985268T priority patent/ES2193114T3/es
Priority to EP00985268A priority patent/EP1153615B1/en
Priority to BR0008249-0A priority patent/BR0008249A/pt
Publication of ES2167189A1 publication Critical patent/ES2167189A1/es
Application granted granted Critical
Publication of ES2167189B1 publication Critical patent/ES2167189B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulación farmacéutica estable para la administración intravenosa o intramuscular, de principios activos péptidos, que se caracteriza porque como vehículo para la inyección del péptido o sus sales farmacéuticamente aceptables, contiene glicina en concentraciones de 10 a 60 mM y solución acuosa de ácido clorhídrico en una cantidad suficiente para ajustar el pH de la formulación a valores entre 3,0 y 4,2.
ES009902769A 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos Expired - Fee Related ES2167189B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES009902769A ES2167189B1 (es) 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
US09/913,439 US6521599B2 (en) 1999-12-17 2000-12-15 Stable pharmaceutical formulation for intravenous or intramuscular administration of active peptide compounds
AU21736/01A AU763779B2 (en) 1999-12-17 2000-12-15 Pharmaceutical formulation for intravenous or intramuscular octreotide administration
AT00985268T ATE233105T1 (de) 1999-12-17 2000-12-15 Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
PT00985268T PT1153615E (pt) 1999-12-17 2000-12-15 Formulacao farmaceutica para administracao intravenosa ou intramuscular de octreotido
DE60001489T DE60001489T2 (de) 1999-12-17 2000-12-15 Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
JP2001544912A JP4912551B2 (ja) 1999-12-17 2000-12-15 活性ペプチド化合物の静脈内および筋内投与のための安定な製剤
PCT/ES2000/000476 WO2001043776A1 (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide
CA2362772A CA2362772C (en) 1999-12-17 2000-12-15 Pharmaceutical formulation for intraveous or intramuscular octreotide administration
MXPA01008349A MXPA01008349A (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.
ES00985268T ES2193114T3 (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.
EP00985268A EP1153615B1 (en) 1999-12-17 2000-12-15 Pharmaceutical formulation for intravenous or intramuscular octreotide administration
BR0008249-0A BR0008249A (pt) 1999-12-17 2000-12-15 Composição farmacêutica estável para aadministração intravenosa ou intramuscular deoctreotida
DK00985268T DK1153615T3 (da) 1999-12-17 2000-12-15 Farmaceutisk formulering til intravenøs eller intramuskulær octreotid-indgivelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009902769A ES2167189B1 (es) 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos

Publications (2)

Publication Number Publication Date
ES2167189A1 true ES2167189A1 (es) 2002-05-01
ES2167189B1 ES2167189B1 (es) 2003-04-01

Family

ID=8310959

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009902769A Expired - Fee Related ES2167189B1 (es) 1999-12-17 1999-12-17 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
ES00985268T Expired - Lifetime ES2193114T3 (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00985268T Expired - Lifetime ES2193114T3 (es) 1999-12-17 2000-12-15 Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide.

Country Status (13)

Country Link
US (1) US6521599B2 (es)
EP (1) EP1153615B1 (es)
JP (1) JP4912551B2 (es)
AT (1) ATE233105T1 (es)
AU (1) AU763779B2 (es)
BR (1) BR0008249A (es)
CA (1) CA2362772C (es)
DE (1) DE60001489T2 (es)
DK (1) DK1153615T3 (es)
ES (2) ES2167189B1 (es)
MX (1) MXPA01008349A (es)
PT (1) PT1153615E (es)
WO (1) WO2001043776A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060363A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for producing sterile polynucleotide based medicaments
AR044852A1 (es) 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
CN101827612A (zh) * 2007-09-07 2010-09-08 联合治疗公司 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法
CN102416001B (zh) * 2011-12-09 2013-06-05 重庆煜澍丰医药有限公司 一种注射用醋酸奥曲肽冻干粉针剂及其制备方法
CN111346214A (zh) * 2020-05-13 2020-06-30 吉林吉力生物技术研究有限公司 一种动物注射用醋酸奥曲肽冻干粉针剂及其制备方法和应用
CN114146054B (zh) * 2020-09-07 2022-12-02 深圳市健元医药科技有限公司 一种醋酸奥曲肽注射液的制备工艺
CN114288385B (zh) * 2021-12-27 2024-01-19 苏州天马医药集团天吉生物制药有限公司 一种醋酸奥曲肽制剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2010561A6 (es) * 1987-07-10 1989-11-16 Sandoz Ag Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
EP0641567A1 (en) * 1993-08-13 1995-03-08 Ciba-Geigy Ag Stable pharmaceutical compositions containing hybrid alpha-interferon
WO1997047317A1 (en) * 1996-06-11 1997-12-18 Novartis Ag Combination of a somatostatin analogue and a rapamycin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2010561A6 (es) * 1987-07-10 1989-11-16 Sandoz Ag Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
EP0641567A1 (en) * 1993-08-13 1995-03-08 Ciba-Geigy Ag Stable pharmaceutical compositions containing hybrid alpha-interferon
WO1997047317A1 (en) * 1996-06-11 1997-12-18 Novartis Ag Combination of a somatostatin analogue and a rapamycin

Also Published As

Publication number Publication date
JP2003517024A (ja) 2003-05-20
DE60001489D1 (de) 2003-04-03
DE60001489T2 (de) 2003-12-04
ES2193114T3 (es) 2003-11-01
EP1153615B1 (en) 2003-02-26
AU2173601A (en) 2001-06-25
CA2362772C (en) 2010-03-16
US20020128204A1 (en) 2002-09-12
CA2362772A1 (en) 2001-06-21
US6521599B2 (en) 2003-02-18
WO2001043776A1 (es) 2001-06-21
EP1153615A1 (en) 2001-11-14
ATE233105T1 (de) 2003-03-15
AU763779B2 (en) 2003-07-31
JP4912551B2 (ja) 2012-04-11
PT1153615E (pt) 2003-06-30
BR0008249A (pt) 2001-10-30
ES2167189B1 (es) 2003-04-01
MXPA01008349A (es) 2004-03-19
DK1153615T3 (da) 2003-06-23

Similar Documents

Publication Publication Date Title
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
WO2002015903A3 (de) Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
WO2003093299A3 (en) Insulin-associated peptides with effects on cerebral health
ES2167189A1 (es) Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
MY132911A (en) Clear, injectable solution of an anesthetic compound
WO2005018657A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
DE69430416T2 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
Hussain et al. An aminoboronic acid derivative inhibits thymopentin metabolism by mucosal membrane aminopeptidases
ES2242973T3 (es) Utilizacion de antagonistas peptidicos de bradiquinina para la preparacion de medicamentos.
WO2005019457A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
US5055449A (en) Vincristine-containing product
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
WO1988004926A1 (en) Nasal delivery of amino acids
WO2005019448A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
MX9707088A (es) Compuestos y composiciones para suministrar agentes activos.
MX9708195A (es) Formulaciones para compuestos lipofilicos y uso de las mismas.
MY152490A (en) New oral formulation
MX9601033A (es) Nanosuspensiones para administracion intravenosa.
HUP9903208A2 (hu) Aminosav tartalmú, immunszuppressziós hatású készítmények és glicin alkalmazása ilyen készítmények előállítására

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2167189B1

Country of ref document: ES

PC2A Transfer of patent

Owner name: GP-PHARM, S.A.

Effective date: 20120906

FD2A Announcement of lapse in spain

Effective date: 20180807